Shots:

• The ongoing P-I GARNET study involves assessing dostarlimab as monothx. in patients with advanced solid tumors. Cohort F of the GARNET trial enrolled patients with dMMR non-endometrial solid cancers in which patients received dostarlimab (500mg- q3w) for four doses and dostarlimab (1000mg- q6w) thereafter for ~2yrs. or until disease progression or discontinuation
• The study demonstrated ORR (38.7%). Additionally- after a median follow-up of 12.4mos.- mDoR had not yet been reached and responses were durable across tumor types
• Dostarlimab is a PD-1 mAb targeting PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 and is under review in the US and EU

 ­ Ref: GSK | Image: GSK